Back to results
US 2014/0154278 A1Published application
Method for allogeneic cell therapy
AssigneeImmunovative Therapies Ltd.
InventorMichael Har-Noy
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeImmunovative Therapies Ltd.
InventorMichael Har-Noy
Estimating the term…
A method of manipulating allogeneic cells for use in allogeneic cell therapy providing a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism, or “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect The anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in a patient.
A method of allogeneic transplant into a host that provides an anti-tumor effect without GVHD toxicity to the host, the method comprising:
A method for stimulating a host immune response against a tumor comprising:
A method for stimulating a coupled host vs. tumor and host vs. graft effect in a host which mirrors the coupled graft vs. tumor and graft vs. host effects of allogeneic transplant procedures comprising:
The method of claim 20 wherein the T-cells are activated by cross-linking of CD3 and CD28 surface antigens.
Dependencies are inferred from the claim text.